CAMBRIDGE, Mass.–(BUSINESS WIRE)–Convergent Therapeutics Inc., a clinical-stage biotechnology company developing next-generation radiopharmaceuticals for the treatment of cancer, today announced compelling results from Part 2 of the Phase 2 CONVERGE-01 study evaluating Ac-225 rosopatamab tetraxetan (CONV01-α) in patients with Lu-PSMA-naïve, androgen pathway modulator-resistant (APMR) prostate cancer. In the study, CONV01-α demonstrated potent anti-tumor activity, including deep prostate speci